GHRP-2 injection (Growth Hormone Releasing Peptide-2) is an artificially synthesized hexapeptide signaling peptide that stimulates the pulsatile secretion of endogenous GH by activating the hexapeptide-2 releasing receptor (GHS-R) in the hypothalamic pituitary axis, mimicking the action of natural ghrelin. Its unique physiological mechanism has demonstrated significant advantages in areas such as muscle gain, fat loss, anti-inflammatory, and tissue repair, but strict adherence to dosage and usage guidelines is necessary to avoid potential risks.
| Product Name | GHRP-2 Powder | GHRP-2 Tablet | GHRP-2 Spray | GHRP-2 Injection |
| Product Type | Powder | Tablet | Spray | Injection |
| Product Purity | ≥99% | ≥99% | ≥99% | ≥99% |
| Product Specifications | 100g/1kg/etc. | 1mg/5mg/10mg/50mg | 1mg/5mg/10mg | 1mg/5mg/10mg |
| Product Form | Organic synthesis | Take Orally | Take Orally | Organic synthesis |
|
|
|
Pralmorelin COA
 |
||
| Certificate of Analysis | ||
| Compound name | Pralmorelin | |
| Grade | Pharmaceutical grade | |
| CAS No. | 158861-67-7 | |
| Quantity | Customized | |
| Packaging standard | Customized | |
| Manufacturer | Shaanxi BLOOM TECH Co., Ltd | |
| Lot No. | 202601090051 | |
| MFG | Jan 9th 2026 | |
| EXP | Jan 8th 2029 | |
| Structure |
|
|
| Item | Enterprise standard | Analysis result |
| Appearance | White or almost white powder | Conformed |
| Water content | ≤5.0% | 0.52% |
| Loss on drying | ≤1.0% | 0.35% |
| Heavy Metals | Pb≤0.5ppm | N.D. |
| As≤0.5ppm | N.D. | |
| Hg≤0.5ppm | N.D. | |
| Cd≤0.5ppm | N.D. | |
| Purity (HPLC) | ≥99.0% | 99.90% |
| Single impurity | <0.8% | 0.47% |
| Total microbial count | ≤750cfu/g | 95 |
| E. Coli | ≤2MPN/g | N.D. |
| Salmonella | N.D. | N.D. |
| Ethanol (by GC) | ≤5000ppm | 500ppm |
| Storage | Store in a sealed, dark, and dry place below -20°C | |
|
|
||
Medical scenario: Treatment of hexapeptide-2 deficiency and related diseases
GHRP-2 injection (hexapeptide-2) injection activates the hypothalamic pituitary axis, simulates the action of ghrelin, and stimulates endogenous GH secretion. Its usage scenarios cover four major fields: medical, sports, anti-aging, and rehabilitation. The specific applications are as follows:
1. Childhood dwarfism
Used to treat GHD in children caused by pituitary insufficiency, such as pituitary dwarfism. By stimulating the pituitary gland to release GH, it promotes bone hexapeptide-2 and height development. The GHRP Kaken 100 developed by Kaken Pharma in Japan has been approved for this type of treatment and has entered phase II clinical trials.
2. Adult GH deficiency
GH deficiency caused by pituitary injury or disease in adults may lead to muscle atrophy, fat accumulation, metabolic disorders, and other problems. By increasing GH levels, improving muscle mass, reducing body fat, and optimizing metabolic indicators such as blood lipids and blood glucose. In 2012, Sella Pharmaceuticals in the United States was also approved for sale for the treatment of adult GH deficiency.
3. Postoperative or trauma recovery
Can accelerate wound healing and reduce the risk of infection. It promotes collagen synthesis and immune cell activation, shortens the postoperative recovery period, and is particularly suitable for elderly patients or those with low immune function.
Sports scenario: muscle gain, fat loss, and improved athletic performance
1. Muscle hexapeptide-2 and strength enhancement
By stimulating the secretion of GH and IGF-1 (insulin-like hexapeptide-2 factor-1), protein synthesis is enhanced and degradation is inhibited, significantly increasing muscle mass. Athletes often inject after training to accelerate muscle repair and hexapeptide-2. Research has shown that when combined with resistance training, it can increase muscle net synthesis rate by 40% -60%.
2. Body fat control
By optimizing fat metabolism, promoting the conversion of white fat to brown fat, and increasing energy expenditure. The user's body fat percentage significantly decreases, especially suitable for athletes in the preparation period. Compared with GHRP-6, it has weaker stimulation on appetite and is more conducive to diet control during the weight loss period.
3. Sports injury rehabilitation
It can alleviate inflammatory reactions and accelerate the repair of soft tissues such as ligaments and tendons. Its anti-inflammatory properties have an auxiliary effect on the recovery of joint injuries such as tennis elbow and running knee.
Anti aging scenario: delaying physiological decline and improving quality of life
1. Skin rejuvenation
Stimulate collagen synthesis, increase skin thickness and elasticity, and reduce wrinkle formation. Combined use of antioxidants (such as vitamin C) can significantly improve skin firmness.
2. Bone density maintenance
By promoting osteoblast activity, inhibiting osteoclast differentiation, and reducing the risk of osteoporosis.
It has a protective effect on the bone health of the elderly population or long-term signaling peptide users (such as glucocorticoids).
3. Cognitive function protection
Animal experiments have shown that it can reduce the deposition of β - amyloid protein and delay the progression of Alzheimer's disease. It improves memory and cognitive function by optimizing cerebral blood flow and neuronal metabolism.
Rehabilitation scenario: Adjuvant treatment for chronic diseases
1. Management of metabolic syndrome
It can improve insulin sensitivity, reduce fasting blood glucose and LDL (low density lipoprotein) levels, and reduce the risk of atherosclerosis. For type 2 diabetes patients, combined diet control can reduce the dosage of hypoglycemic drugs.
2. Non alcoholic fatty liver disease (NAFLD)
By reducing liver enzyme levels and minimizing liver fat infiltration, liver function indicators can be improved. Its mechanism is related to GH promoting fat breakdown and inhibiting hepatic gluconeogenesis.
3. Immune function regulation
(DES-ALA3)-KP-102 can enhance macrophage phagocytic function, balance immune response, and reduce the risk of recurrent infections. It has adjuvant therapeutic value for immunocompromised patients (such as HIV infected individuals).
Dosage regimen and usage guidelines
Injection timing and cycle
Time window: Accurately grasp physiological rhythms and maximize GH release efficiency
The timing of GHRP-2 injection should strictly follow the physiological rhythm and metabolic status to enhance GH release effect in a hypoglycemic environment. The specific suggestions are as follows:
Early morning fasting injection
Early morning (6:00-8:00) is the peak period of natural GH secretion in the human body, during which injection can be combined with endogenous pulses to form a "dual stimulus". Before injection, it is necessary to ensure a fasting state (at least 8 hours without eating) to avoid blood sugar fluctuations interfering with GH release.
Immediate injection after training
Within 30 minutes after high-intensity training, muscles are in a "nutrient window period", during which injection can accelerate the transport of amino acids to muscle cells and promote protein synthesis. If the training time is late (such as at night), the injection time should be adjusted based on the fasting state (such as injecting directly after training and then fasting for 1 hour).
Bedtime injection
Injecting 1 hour before bedtime can simulate the natural secretion pattern of GH at night, optimize sleep quality, and promote nighttime repair. Attention should be paid to avoiding consumption with high sugar foods to prevent high blood sugar from inhibiting GH release.
Cycle design: dynamic adjustment to balance efficacy and safety
Wash off period
After the cycle ends, a 4-6 week "wash off period" is required, during which (DES-ALA3)-KP-102 is discontinued to allow pituitary receptors to regain sensitivity and avoid desensitization caused by long-term stimulation.
Long term monitoring
Long term users (exceeding 2 standard cycles) need to have their serum IGF-1 levels tested every 3 months to ensure they remain within the physiological range (114-492 ng/mL).
If IGF-1 remains above the upper limit, it is necessary to shorten the cycle or reduce the dose; If it is below the lower limit, the absorption efficiency needs to be evaluated or the medication regimen needs to be adjusted.
Injection method and location
Technical point: Standardized operation to reduce the risk of complications
Subcutaneous injection: The needle is inserted at a 45 degree angle, with a depth of about 5-8mm (adjusted according to the thickness of subcutaneous fat), ensuring that the medication is injected into the fat layer rather than the muscle layer. Subcutaneous injection has a moderate absorption rate and can maintain the sustained effect of GH release.
Avoid intramuscular injection: Intramuscular injection (90 degree angle injection) can lead to rapid absorption of the medication, high peak GH release but short duration, which may increase the risk of side effects such as edema and joint pain.
Commonly used areas: abdomen (5cm outside the navel), outer thigh, and upper outer quadrant of the buttocks.
Rotation principle: Inject the same area no more than 3 times in a row, with a minimum interval of 2cm between each injection, to reduce subcutaneous fat atrophy or induration formation. If hardening occurs, local hot compress or external application of low molecular weight heparin sodium ointment can be used.
Before injection, use 75% alcohol swabs to disinfect the injection site in a spiral pattern from the inside out. After the alcohol evaporates, inject to avoid irritation to the skin caused by residual alcohol.
During the injection process, sterile gloves should be worn to avoid touching the needle or medication to prevent contamination.
Equipment selection: precise dose control and solvent safety
Recommended use: 1ml insulin syringe (with fine scale up to 10mcg), suitable for precise injection of small doses (such as 100-300mcg).
Alternative solution: If a large dose (such as ≥ 500mcg) needs to be injected, a 3ml syringe can be used, but the medication needs to be pre packaged to avoid waste.
Preferred solvents: sterile injection water (without preservatives) or bacterial still water (containing 0.9% benzyl alcohol), the latter can extend the shelf life of the drug solution to 2-3 weeks (requiring refrigeration).
Taboo solvents: solvents containing strong preservatives such as phenol and meta cresol may damage the molecular structure of (DES-ALA3)-KP-102 and reduce its biological activity.
When dissolving, slowly inject solvent along the bottle wall to avoid the formation of foam due to direct impact on the powder.
Shake the bottle gently until completely dissolved (do not shake vigorously). After dissolution, the medicine should be transparent and particle free, otherwise it needs to be re prepared.
Advanced suggestion: Individualized adjustment and risk warning
Dose adjustment
Adjust the dose dynamically based on body weight, training intensity, and IGF-1 levels. For example, individuals with a weight greater than 90kg or high-intensity training can increase the single dose to 250-300mcg.
Side effect warning
If persistent edema, joint pain, or blood glucose fluctuations occur, medication should be immediately suspended and IGF-1, prolactin, and fasting blood glucose should be tested.
Combination therapy
When used in combination with GHRH analogs (such as CJC-1295), the dose of (DES-ALA3)-KP-102 should be reduced by 30% -50% to avoid receptor depletion caused by excessive GH release.
By strictly following the above specifications, the efficacy of GHRP-2 injection can be maximized while minimizing the risk of side effects, achieving the goal of safe and efficient physiological optimization.
FAQ
What is this drug vused for?
Pralmorelin is marketed under the brand name GHRP in Japan. It is used as a diagnostic agent in a single-dose formulation for the assessment of growth hormone deficiency (GHD). Pralmorelin (GHRP2) acts to endogenously increase growth signaling peptide release from the pituitary.
What are the side effects of this?
Pralmorelin (GHRP2) side effects commonly include injection site reactions (pain, redness, swelling), increased hunger, fatigue, nausea, and headache. More serious risks involve water retention, potential increases in blood sugar, and rare allergic reactions. It may cause temporary increased cortisol and prolactin.
What does the GHRP-2 injection do?
GHRP2 (Growth Hormone Releasing Peptide-2) is a synthetic agonist of the ghrelin receptor that potently stimulates the pituitary gland to release higher levels of growth hormone (GH). It increases appetite, promotes lean muscle development, enhances fat loss, and speeds up injury recovery.
Is this med the same as Sermorelin?
GHRP2 and Sermorelin are both peptides used to increase growth hormone (GH) levels, but they operate through different pathways. GHRP2 is a powerful synthetic ghrelin-mimetic that directly stimulates the pituitary, often increasing appetite. Sermorelin is a GHRH analog that encourages natural, pulsatile signaling peptide release with fewer side effects. They are sometimes paired for synergistic results.
Hot Tags: ghrp-2 injection, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale